Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD7 CAR-T in CD7+ Hematological Malignancies
NCT05454241Phase 2Completed
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Sep 2022
- Primary completion
- Aug 2024
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of CD7-CAR T cells in hematologic malignancy, sponsored by Institute of Hematology and Blood Diseases Hospital. Started Sep 2022; status: completed.
02
Drugs
CD7-CAR T cells
03
Conditions
hematologic malignancy
Beyond the preview
Go deeper on NCT05454241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05454241.